Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Evidence xmlns="http://hl7.org/fhir">
<id value="293987"/>
<meta>
<versionId value="3"/>
<lastUpdated value="2024-12-14T08:46:28.847Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Evidence 293987</b></p><a name="293987"> </a><a name="hc293987"> </a><a name="293987-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 3; Last updated: 2024-12-14 08:46:28+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-intervention-only-evidence.html">InterventionOnlyEvidence</a></p></div><p><b>url</b>: <a href="https://fevir.net/resources/Evidence/293987">https://fevir.net/resources/Evidence/293987</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/293987, outcomeId/313963, picoId/85798, sectionId/73215</p><p><b>name</b>: Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963</p><p><b>title</b>: MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 InterventionOnlyEvidence}">InterventionOnlyEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><h3>RelatedArtifacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style="display: none">*</td><td>Part Of</td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes -- SGLT2 inhibitors</p>
</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="Group-236949.html">SGLT2 inhibitors Group in Adults with type 2 diabetes</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Serious hyperglycaemia</p>
</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href="EvidenceVariable-236974.html">Serious hyperglycaemia</a></p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Description</b></td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><div><p>Risk 1.5%</p>
</div></td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/statistic-type C44256}">Proportion</span></td><td>0.015</td></tr></table></div>
</text>
<url value="https://fevir.net/resources/Evidence/293987"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="urn:ietf:rfc:3986"/>
<value value="https://fevir.net/FOI/293987"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<type>
<text value="outcomeId"/>
</type>
<system value="https://app.magicapp.org/#/guidelines"/>
<value value="313963"/>
</identifier>
<identifier>
<type>
<text value="picoId"/>
</type>
<system value="https://app.magicapp.org/#/guidelines"/>
<value value="85798"/>
</identifier>
<identifier>
<type>
<text value="sectionId"/>
</type>
<system value="https://app.magicapp.org/#/guidelines"/>
<value value="73215"/>
</identifier>
<name
value="Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963"/>
<title
value="MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
<status value="active"/>
<publisher value="Computable Publishing LLC"/>
<contact>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</contact>
<author>
<name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
</author>
<useContext>
<code>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="evidence-communication"/>
<display value="Evidence Communication"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="InterventionOnlyEvidence"/>
<display value="InterventionOnlyEvidence"/>
</coding>
</valueCodeableConcept>
</useContext>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<relatedArtifact>
<type value="part-of"/>
<resourceReference>
<type value="Composition"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-conversion-report"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
</resourceReference>
</relatedArtifact>
<description
value="This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
<variableDefinition>
<description value="Adults with type 2 diabetes -- SGLT2 inhibitors"/>
<variableRole value="population"/>
<observed>🔗
<reference value="Group/236949"/>
<type value="Group"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85394-I-85798"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</observed>
</variableDefinition>
<variableDefinition>
<description value="Serious hyperglycaemia"/>
<variableRole value="outcome"/>
<observed>🔗
<reference value="EvidenceVariable/236974"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313963"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="Serious hyperglycaemia"/>
</observed>
</variableDefinition>
<statistic>
<description value="Risk 1.5%"/>
<statisticType>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/statistic-type"/>
<version value="5.0.0-cibuild"/>
<code value="C44256"/>
<display value="Proportion"/>
</coding>
</statisticType>
<quantity>
<value value="0.015"/>
</quantity>
</statistic>
</Evidence>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change